ArticleRSC advances2023
Facile one pot synthesis of 2-substituted benzimidazole derivatives under mild conditions by using engineered MgO@DFNS as heterogeneous catalyst.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 20 citations in OpenAlex.
- Design of a novel tribromide ionic liquid covalent triazine framework for green synthesis of benzimidazoles.RSC advances · 2026Article
- Catalyst-Assisted Synthesis of Benzimidazole Derivatives: Recent Advances and Mechanistic Insights.Topics in current chemistry (Cham) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzimidazole derivatives are considered as important heterocyclic motifs that show a wide range of pharmaceutical applications. In view of their wide-ranging bioactivities, it is imperative to direct research on the sustainable catalytic synthesis of benzimidazole. Therefore, herein, we report a novel approach for the synthesis of benzimidazole and its derivatives with engineered MgO supported on dendritic fibrous nano silica (MgO@DFNS) as a sustainable heterogeneous catalyst. The catalyst MgO@DFNS was thoroughly characterized to understand its physio-chemical properties using XRD, FE-SEM, XPS, FT-IR, zeta potential, HR-TEM, TGA, TPR and TPD. The obtained results suggested that the catalyst MgO@DFNS prepared well and have the desired characteristics in it. After the successful characterisation of the prepared catalyst MgO@DFNS, it was applied in the synthesis of benzimidazole derivatives
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.